The Influence of Haemostatic System Maturation on the Dose–Response Relationship of Unfractionated Heparin

• Published in: Clinical pharmacokinetics Vol. 60; no. 4; pp. 491 - 499
• Main Authors: Derbalah, Abdallah, Duffull, Stephen, Moynihan, Katie, Al-Sallami, Hesham
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.04.2021; Springer Nature B.V
• Subjects: Adults; Age; Anticoagulants; Drug dosages; Extracorporeal membrane oxygenation; Influence; Internal Medicine; Medicine; Medicine & Public Health; Ordinary differential equations; Original Research Article; Pediatrics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Australia
• ISSN: 0312-5963; 1179-1926; 1179-1926
• DOI: 10.1007/s40262-020-00949-0

Background Unfractionated heparin (UFH) dosing and monitoring guidelines for children are often extrapolated from adult data. This practice is suboptimal given the inherent differences in haemostatic maturation and drug handling in children compared with adults. Objective The aim of this work was to investigate the impact of haemostatic system maturation on the dose–response relationship of UFH in children. Methods A quantitative model for haemostasis in adults was adapted to account for maturation in UFH pharmacokinetic (PK) parameters with and without age-related changes in coagulation factor concentrations. The adult and adapted models were used to predict the time courses of anti-factor Xa activity (aXa) and activated partial thromboplastin time (aPTT) in patients receiving UFH infusion. Predictions from both models were compared with observed aXa and aPTT measurements from 31 paediatric patients receiving UFH during extracorporeal membrane oxygenation (ECMO). Results The model with maturation for both UFH PK and the haemostatic system had an improved aXa and aPTT predictive performance compared with maturation in UFH PK only and the original adult model. Despite the minor effect of haemostatic system maturation on baseline aPTT, it led to substantial changes in the time course of aPTT sensitivity to UFH. This finding suggests that between-subject variability in clotting factors concentrations is potentially a major contributor to the overall variability of aPTT response to UFH. In addition, time-varying clotting factors concentrations may explain within-subject changes in aPTT sensitivity to UFH. Conclusion We developed the first quantitative systems pharmacology (QSP) model that provides a mechanistic and quantitative basis for linking physiological and pharmacological maturation to UFH effect and response biomarkers. After appropriate clinical validation, the model could be useful for the development of paediatric-specific individualised UFH dosing recommendations.